OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple Myeloma

March 9th 2021

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Dr. Philip on the Emerging Role of ctDNA in CRC

March 9th 2021

Tony Philip, MD, discusses the emerging role of circulating tumor DNA in colorectal cancer.

Dr. Borgen on Treatment Strategies for Male Breast Cancer

March 9th 2021

Patrick Borgen, MD, discusses treatment strategies for patients with male breast cancer.

Dr. Grothey on the Potential Utility of TAS-102/Bevacizumab in Metastatic CRC

March 8th 2021

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Dr. Mead on the Utility of Second-Line Venetoclax/Rituximab in CLL

March 5th 2021

Monica D. Mead, MD, discusses the utility of venetoclax in combination with rituximab in the second-line setting for patients with chronic lymphocytic leukemia.

Dr. Jones on Selecting Between Frontline Regimens in Pancreatic Cancer

March 5th 2021

Amy Jones, MD, discusses factors that can inform frontline treatment selection in pancreatic cancer.

Dr. Martin on the Potential Role of LOXO-305 in MCL

March 5th 2021

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Dr. Till on the Potential to Utilize CAR T-Cell Therapy Earlier in MCL

March 4th 2021

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.

Dr. Bociek on Reserving Allo-SCT for Certain Patients with CLL

March 4th 2021

R. Gregory Bociek, MD, discusses the rationale to reserve allogeneic stem cell transplant for certain patients with chronic lymphocytic leukemia.

Dr. Bekaii-Saab on the Toxicity Differences Between Regorafenib and TAS-102 in CRC

March 4th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Spira on the Challenges of Developing NRG1 Fusion–Directed Therapies in NSCLC

March 3rd 2021

Alexander Spira, MD, PhD, FACP, discusses the challenges of developing targeted therapies for patients with NRG1 fusion–positive non–small cell lung cancer.

Dr. Grothey on Dosing Strategies With Regorafenib in CRC

March 3rd 2021

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC

March 2nd 2021

Alexander Spira, MD, PhD, FACP, discusses the efficacy of mobocertinib in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC

March 2nd 2021

Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

Dr. Singal on the Utility of Frontline Lenvatinib and Sorafenib in Advanced HCC

March 2nd 2021

Amit G. Singal, MD, MS, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma.

Dr. Richardson on the FDA Approval of Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

March 1st 2021

Paul G. Richardson, MD, discusses the FDA approval of melphalan flufenamide in relapsed/refractory multiple myeloma.

Dr. Krivak on the Importance of Germline Genetic Testing in Ovarian Cancer

March 1st 2021

Thomas C. Krivak, MD, discusses the importance of germline genetic testing in ovarian cancer.

Dr. Martin on Potential Combination Strategies With BTK Inhibitors in MCL

March 1st 2021

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

Dr. Dhakal on the Mechanism of Action of Orva-Cel in Multiple Myeloma

February 26th 2021

Binod Dhakal, MD, discusses the mechanism of action of orvacabtagene autoleucel in multiple myeloma.

Dr. Ip on the Challenges of Treating Patients With Hematologic Malignancies and COVID-19

February 25th 2021

Andrew Ip, MD, MS, discusses the challenges of treating patients with hematologic malignancies and COVID-19.